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Research
Even moderately elevated concentrations 
of inorganic arsenic (iAs) in drinking water 
are of major public health concern world-
wide [World Health Organization (WHO) 
2001]. In Bangladesh alone, more than 50 
million inhabi  tants are drinking water that 
contains arsenic above the WHO guideline 
value of 10 µg/L [British Geological Survey 
(BGS) 2001; Chakraborti et al. 2004]. In 
addition, there is increasing concern about 
arsenic exposure from food, especially rice 
products (Sun et al. 2008). Chronic arsenic 
exposure is associated with an increased risk 
of cancer of the skin, lungs, bladder, liver, 
and possibly kidneys [International Agency 
for Research on Cancer (IARC) 2004a], as 
well as a number of noncarcinogenic effects 
(Rahman et al. 2007; States et al. 2009; 
WHO 2001). The earliest signs of toxicity 
from chronic exposure to iAs in humans are 
pigmentation changes and hyperkeratosis, 
which may proceed to skin cancer (Yu et al. 
2006). Unlike the arsenic-related cancers, 
which may appear first after two to three 
decades of exposure, these skin lesions may 
appear within a few years of exposure (Chen 
et al. 2006; Saha 2003).
A wide variation appears to exist in suscepti-
bility to arsenic-induced toxicity. The best docu-
mented risk-modifying factor for arsenic-related 
health effects is the metabolism of arsenic. iAs is 
methylated via one-carbon metabolism using 
arsenic (III) methyl  transferase (AS3MT). The 
main metabo  lites excreted in urine are methyl-
arsonic acid (MA) and dimethyl  arsinic acid 
(DMA), besides some unmethylated iAs, but 
major differences exist between individuals and 
population groups (Vahter 2002). Numerous 
studies have demon  strated positive associa-
tions between the percentage of MA in urine 
and various cancers, chromosome aberrations, 
and oxidative stress (Chen et al. 2003a, 2003b, 
2005a, 2005b; Chung et al. 2008; Hsueh 
et al. 1997; Huang et al. 2008; Li et al. 2008; 
Mäki-Paakkanen et al. 1998; Pu et al. 2007; 
Steinmaus et al. 2006; Xu et al. 2008; Yu 
et al. 2000). Two recent studies (Ahsan et al. 
2007; Lindberg et al. 2008b) also reported 
increased risk for pigmentation changes and 
hyper  keratosis.
Another known risk-modifying factor 
is cigarette smoking. For quite some time, 
researchers have known that concurrent expo-
sure to arsenic and smoking synergistically 
increases the risk of lung cancer (Mostafa et al. 
2008; Pershagen et al. 1987), and experimental 
studies showed that arsenic and cigarette smoke 
at environmentally relevant levels act synergisti-
cally to cause DNA damage (Hays et al. 2006). 
Similarly, bladder cancer seemed to be signifi-
cantly associated with arsenic exposure among 
smokers only (Bates et al. 2004; Steinmaus 
et al. 2003). Recently, an interaction between 
elevated arsenic exposure via drinking water 
and tobacco smoking was indicated also for the 
induction of skin lesions (Chen et al. 2006).
It was recently reported that the well- 
documented less efficient methylation of arse-
nic in men, compared with women (Vahter 
et al. 2007), is the main reason for the 
observed higher prevalence of skin lesions in 
men (Lindberg et al. 2008b). Because smok-
ing has been associated with less efficient 
arsenic methyla  tion (Hopenhayn-Rich et al. 
1996; Lindberg et al. 2008a), we evaluated 
potential inter  actions between smoking and 
arsenic metabolism for the risk of developing 
skin lesions.
Materials and Methods
Study population. This study is part of a popu-
lation-based case–referent study concerning 
the development of skin lesions in relation to 
arsenic exposure via drinking water carried 
out in Matlab, a rural area 53 km southeast 
of Dhaka, Bangladesh (Rahman et al. 2006a, 
2006b). More than 60% of the tube wells in 
this area have concentrations above 50 µg/L, 
which is the Bangladeshi standard for drinking 
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Ba c k g r o u n d: We recently reported that the main reason for the documented higher prevalence 
of arsenic-related skin lesions among men than among women is the result of less efficient arsenic 
metabolism. 
oB j e c t i v e: Because smoking has been associated with less efficient arsenic methylation, we aimed 
to elucidate interactions between tobacco use and arsenic metabolism for the risk of developing skin 
lesions. 
Me t h o d s : We used a population-based case–referent study that showed increased risk for skin 
lesions in relation to chronic arsenic exposure via drinking water in Bangladesh and randomly 
selected 526 of the referents (random sample of inhabitants > 4 years old; 47% male) and all 504 
cases (54% male) with arsenic-related skin lesions to measure arsenic metabolites [methylarsonic 
acid (MA) and dimethylarsinic acid (DMA)] in urine using high-performance liquid chromatogra-
phy (HPLC) and inductively coupled plasma mass spectrometry (ICPMS).
re s u l t s: The odds ratio for skin lesions was almost three times higher in the highest tertile of 
urinary %MA than in the lowest tertile. Men who smoked cigarettes and bidis (locally produced 
cigarettes; 33% of referents, 58% of cases) had a significantly higher risk for skin lesions than did 
nonsmoking men; this association decreased slightly after accounting for arsenic metabolism. Only 
two women smoked, but women who chewed tobacco (21% of referents, 43% of cases) had a con-
siderably higher risk of skin lesions than did women who did not use tobacco. The odds ratio (OR) 
for women who chewed tobacco and who had ≤ 7.9 %MA was 3.8 [95% confidence interval (CI), 
1.4–10] compared with women in the same MA tertile who did not use tobacco. In the highest 
tertile of %MA or %inorganic arsenic (iAs), women who chewed tobacco had ORs of 7.3 and 7.5, 
respectively, compared with women in the lowest tertiles who did not use tobacco. 
co n c l u s i o n: The increased risk of arsenic-related skin lesions in male smokers compared with non-
smokers appears to be partly explained by impaired arsenic methylation, while there seemed to be 
an excess risk due to interaction between chewing tobacco and arsenic metabolism in women.
key w o r d s : arsenic, interactions, metabolism, skin lesions, smoking, tobacco, urine metabolites. 
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water, and 70% are above the WHO maxi-
mum guideline of 10 µg As/L. In Matlab, the 
International Centre for Diarrhoeal Disease 
Research, Bangladesh (ICDDR,B) has 
been running a comprehensive Health and 
Demographic Surveillance System (HDSS) 
that covers a population of 220,000. 
We obtained informed consent from all 
participants, and the study was approved by 
both the ICDDR,B Ethical Review Committee 
and the ethics committee at the Karolinska 
Institutet in Stockholm. Mitigating activities 
such as painting wells with elevated arsenic 
concentrations and installing filters were ini-
tiated as described elsewhere (Jakariya et al. 
2005; Rahman et al. 2006b).
Cases and referents recruitment. The 
recruitment of persons with skin lesions (504 
cases) and the selection of referents (1,830 
referents) are described elsewhere (Rahman 
et al. 2006a). In short, all residents > 4 years 
of age who had lived in the study area for at 
least 6 months were eligible for the present 
study (180,811 individuals). In total, 166,934 
(92%) of the eligible individuals were inter-
viewed and examined for skin lesions by 
well-trained field teams, and 1,682 suspected 
cases were referred to the study physicians 
(one male and one female) at the health cen-
ters. Eventually, 504 cases were diagnosed 
with arsenic-induced skin lesions (defined as 
hyperpigmentation, hypopigmentation, and 
keratosis). For details regarding the ascertain-
ment of cases, see Rahman et al. (2006a). All 
cases provided urine samples. Referents were 
randomly selected from the HDSS database 
with the criteria of more than 4 years of age, 
living in the area for at least 6 months, and 
drinking water from the area at least once a 
week. Selected referents were interviewed and 
invited to attend the clinic to be examined 
for skin lesions by a physician and to pro-
vide urine samples. A total of 1,579 referents 
attended the clinic. 
Data collection. The field teams inter-
viewed all individuals about their history of 
water consumption and the water sources 
used, including location, during each cal-
endar year since 1970 or since birth if later 
than 1970, as described previously in more 
detail (Rahman et al. 2006b). Data on socio-
economic status (SES) were collected from the 
HDSS database and were defined in terms of 
assets relevant to these rural settings (Rahman 
et al. 2006b). Information on tobacco use, 
obtained in the interviews, was divided into 
cigarette smoking, bidi (locally produced ciga-
rettes) smoking, or chewing tobacco, the latter 
consisting of dried tobacco leaves or zarda (a 
type of chewing tobacco, often used with areca 
nut, slaked lime, and betel leaves). Water sam-
ples were collected from all functional wells 
in the area and stored at –20°C (n = 13,286). 
Arsenic concentrations in drinking water were 
determined using atomic absorption spectrom-
etry with hydride generation, with addition of 
hydrochloric acid and potassium iodine com-
bined with heating (Wahed et al. 2006). For 
samples with concentrations below the limit of 
detection (LOD; 1.0 µg/L), half the LOD was 
used in the calculations.
Arsenic exposure. Both the average and 
the cumulative historical arsenic exposure 
were calculated as the time-weighted mean 
arsenic concentration of drinking water of all 
sources used since 1970 or birth. The cumula-
tive arsenic exposure was calculated by sum-
ming the arsenic concentration multiplied by 
the number of years of usage (micrograms per 
liter × years) for all water sources used since 
1970. From the interviews of the participants 
regarding their water consumption history, 
we were able to collect data on which year the 
participant started to drink well water (after 
1970) and thereby the age at first exposure 
to tube well water. Very few wells were con-
structed before 1970, at which time the regis-
tration of the wells in the HDSS began. 
Urine arsenic measures. Spot urine samples 
were collected in 20 mL polyethylene contain-
ers and stored at –20°C. We randomly selected 
526 samples from all referents and all 504 cases 
for analysis of arsenic metabolites in urine for 
evaluation of the individual arsenic methylation 
efficiency. The individual pattern of arsenic 
metabolites in urine is shown to be fairly stable 
over time (Concha et al. 2002; Kile et al. 2009; 
Steinmaus et al. 2005). Speciation analysis of 
arsenic metabolites in urine was performed 
by an inductively coupled plasma mass spec-
trometer (ICP-MS; Agilent 7500ce, Agilent 
Technologies, Waldbronn, Germany) together 
with an Agilent 1100 chromatographic sys-
tem equipped with solvent degasser, auto sam-
pler, and temperature-controlled column. For 
the separation of trivalent arsenic [As(III)], 
MA, DMA, and pentavalent arsenic [As(V)], 
a Hamilton PRP-X100 anion exchange col-
umn (4.6 mm × 250 mm) was used (Lindberg 
et al. 2006, 2007). For quality control, we 
used a Japanese reference urine certified for 
arsenic (Yoshinaga et al. 2000) and a spiked 
urine sample. Mean concentrations of As(III), 
DMA, MA, and As(V) in the reference urine 
were 3.9 ± 0.4, 43 ± 3, 3.0 ± 0.4, and 0.1 ± 0.1 
(n = 79 during an 8-week period), respectively. 
The mean concentrations of the spiked urine 
samples of As(III), DMA, MA, and As(V) 
were 1.5 ± 0.6, 58 ± 3, 10 ± 0.6, and 16 ± 1.3 
(n = 82 during an 8-week period), respectively. 
The results of interlaboratory comparisons are 
described in more detail elsewhere (Lindberg 
et al. 2007). Arsenic concentrations in urine 
were adjusted to the average specific gravity in 
this population (1.012 g/cm3), as measured by 
a refractometer (Uricon-Ne, ATAGO Co. Ltd, 
Tokyo, Japan) to adjust for variation in dilu-
tion in the urine samples (Nermell et al. 2008). 
We also measured the arsenic concen-
trations of various forms of cigarettes, using 
ICP-MS after microwave-assisted acid diges-
tion at high temperature and pressure as pre-
viously described for blood and breast milk 
(Fangstrom et al. 2008). 
Statistical analyses. We used SPSS 14.0 
for Windows (SPSS Inc., Chicago, IL, USA) 
to perform all statistical analyses. Multivariate 
logistic regression analyses were performed 
to estimate the odds ratios (ORs) and cor-
responding confidence intervals (CIs) for 
having skin lesions at different proportions 
of arsenic metabolites in urine. Continuous 
variables were stratified into tertiles when esti-
mating the ORs for having skin lesions. All 
multi  variate associations were simultaneously 
adjusted for sex (man/woman), age (continu-
ous), SES (continuous), tobacco use (no/yes), 
and cumulative arsenic exposure (continuous). 
We chose to adjust all models for cumulative 
arsenic exposure instead of average arsenic 
exposure or urinary arsenic concentrations. 
The cumulative arsenic exposure influenced the 
associations slightly more than did the average 
arsenic exposure, and adjusting for the urinary 
arsenic concentrations did not make any dif-
ference in the models when tested (data not 
shown). We calucated p for trend by treating 
the cate  gorical variables as continuous variables 
in the models. To evaluate potential biologic 
interactions between the different risk factors, 
that is, arsenic metabolism and smoking, on 
arsenic-related skin lesions, we calculated the 
relative excess risk due to additive interactions 
(RERI) and corresponding CIs (Ahlbom and 
Alfredsson 2005). These calculations were per-
formed according to Andersson et al. (2005), 
using an Excel sheet (EpiNET 2008). We used 
p-values < 0.05 for statistical significance.
Results
Sex-specific characteristics of the cases and ref-
erents are presented in Table 1. The cases were 
more often men than women (54% vs. 46%) 
and older than the referents (overall, 40 vs. 31 
years old). The cases also had higher SES, as 
measured by household asset scores, and they 
smoked cigarettes or bidis (men only) or used 
zarda more often than did the referents. The 
three different measures of arsenic exposure, 
that is, cumulative lifetime exposure to arsenic 
in drinking water (micrograms per liter × years), 
average lifetime exposure to arsenic (micro-
grams per liter), and current total exposure to 
iAs, as measured by the concentration of arse-
nic metabolites in urine, are also presented in 
Table 1. The cases had significantly higher life-
time cumulative arsenic exposure and average 
lifetime arsenic exposure than did the referents 
but not higher urinary arsenic concentrations.
The number of years of tobacco use and 
the number of tobacco products used per 
day among cases and referents are shown in Tobacco use and arsenic-induced skin lesions
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Supplemental Material, Table S1 (doi:10.1289/
ehp.0900728). The pattern of tobacco use dif-
fered markedly between men (46% smokers, 
11% chewing tobacco) and women [only two 
female smokers, 31% chewing tobacco (see 
Supplemental Material, Table S2)]. We ana-
lyzed men and women separately. The asso-
ciations between the different forms of tobacco 
use and urinary arsenic metabolites are shown 
in Table 2. All forms of tobacco use were asso-
ciated with an increased percentage of MA and 
a decreased percentage of DMA, whereas the 
percentage of iAs and the urinary arsenic con-
centration did not vary much by tobacco use.
Men who smoked cigarettes or bidis had 
significantly higher risk for skin lesions than 
did men who did not use tobacco (OR = 1.8; 
95% CI, 1.1–3.1; adjusted for age, SES, 
and cumulative arsenic exposure; Table 3). 
We observed a marked drop in the OR after 
adjusting for age, SES, and cumulative arsenic 
exposure (crude OR = 3.2). Entering the dif-
ferent covariables independently showed that 
age was the main confounding factor. The 
adjusted OR in men chewing tobacco was not 
significantly increased (adjusted OR = 0.80; 
95% CI, 0.36–1.7; Table 3); however, the 
number of individuals was low. Because very 
few women smoked, we could not deter-
mine the effect on the risk for skin lesions 
among women. The multivariable-adjusted 
model that included all women who used 
tobacco (mainly chewing tobacco) showed 
that they had considerably higher prevalence 
of skin lesions than did women who did not 
use tobacco (adjusted OR = 2.4; 95% CI, 
1.4–3.9; Table 3). Excluding the two women 
who smoked cigarettes did not change the 
associations. To test for the influence of arse-
nic methylation on the association between 
tobacco use and arsenic-related skin lesions, 
we also adjusted the OR values for %MA 
in urine. As shown in Table 3, the OR for 
men who smoked changed from 1.8 to 1.4 
(95% CI, 0.80–2.4) after additional adjust-
ment for %MA. Compared with women who 
did not use any tobacco, the OR for women 
who chewed tobacco changed from 2.4 to 2.0 
(95% CI, 1.2–3.4) after adjusting for %MA 
and remained significantly increased.
To further evaluate interactions between 
smoking and arsenic metabolism on the risk 
for skin lesions, we stratified both tobacco use 
and urinary arsenic metabolites and analyzed 
the joint effects. The increasing risk for skin 
lesions with increasing proportion of MA and 
decreasing proportion of DMA was more pro-
nounced among nontobacco using men and 
women (Table 4). The OR for men who used 
tobacco (mostly smokers, because few chewed 
tobacco) with ≤ 7.9 %MA was 1.8 (95% CI, 
0.53–6.3; p = 0.34), compared with men in the 
same tertile of %MA who did not use tobacco. 
Men within the highest tertile of %MA who 
used tobacco had an OR of 4.4 (95% CI,   
1.7–11). This OR was essentially the same as 
the sum of the OR for non  tobacco users in the 
highest %MA tertile and that for tobacco users 
in the lowest %MA tertile minus the baseline 
OR (OR values 3.8 + 1.8 – 1.0 = 4.6). Similar 
results were obtained for %iAs; the ORjoint 
was 2.8, which is approximately equal to the 
sum (minus 1) of the OR for nonsmokers in 
the highest %iAs tertile (OR 1.6) and that 
for smokers in the lowest %iAs (OR = 1.9). 
Among women, the OR for tobacco users 
(mainly chewing tobacco) with ≤ 7.9 %MA 
in urine was 3.8 (95% CI, 1.4–10), compared 
Table 1. ORs (95% CIs) for skin lesions by characteristics of case–referent participants (504 cases, 
528   referents).
Male Female
Groupa Referents (n) Cases (n) ORcrude (95% CI) Referents (n) Cases (n) ORcrude (95% CI)
Age (years)
≤ 18 93 3 1.0 85 8 1.0
18–39 68 116 53 (16–173)** 105 110 11 (5–24)**
> 39 88 153 54 (17–175)** 89 114 14 (6–30)**
SESb
≤ –0.60 80 50 1.0 93 42 1.0
–0.60 to 0.74 81 77 1.5 (0.95–2.4) 91 81 2.0 (1.2–3.2)**
> 0.74 76 136 2.9 (1.8–4.5)** 86 99 2.5 (1.6–4.1)**
Tobacco use
None 142 83 1.0 220 132 1.0
Cigarettes 39 93 4.1 (2.6–6.5)** 1 0 —
Bidi 44 64 2.5 (1.6–4.0)** 1 0 —
Chewing tobacco 24 32 2.3 (1.3–4.1)** 57 100 2.9 (2.0–4.3)**
CumAsc
≤ 1,639 86 51 1.0 90 29 1.0
1,639–4,107 81 45 0.94 (0.57–1.5) 95 55 1.8 (1.1–3.1)*
> 4107 82 176 3.6 (2.3–5.6)** 94 148 4.9 (3.0–8.0)**
AverageAsd
< 80 84 67 1.0 94 43 1.0
80–181 80 54 0.85 (0.53–1.4) 92 74 1.8 (1.1–2.8)*
> 181 85 151 2.2 (1.5–3.4)** 93 115 2.7 (1.7–4.3)**
U-Ase
≤ 51 78 87 1.0 96 80 1.0
51–124 90 75 0.75 (0.49–1.2) 89 56 0.76 (0.48–1.2)
> 124 81 110 1.2 (0.80–1.9) 94 96 1.2 (0.81–1.8)
aTertiles of referents. bValues refer to household assets. cCumulative arsenic exposure (µg/L × years). dAverage lifetime 
arsenic exposure (µg/L). eSum of arsenic metabolites in urine (µg/L). *p < 0.05. **p < 0.01. 
Table 2. Pattern of arsenic metabolites (percentages of iAs, MA, DMA) in urine, by tobacco use and sex.
U-As (µg/L) %iAs  %MA %DMA
Group n Median Mean ± SD Median Mean ± SD Median Mean ± SD Median
Men
Nonea 225 81.2 13.1 ± 7.0 11.4 11.8 ± 5.5 10.9 75.1 ± 10.1 77.1
Cigarettes 132 97.8 14.2 ± 7.4 12.9 16.2 ± 5.6** 16.0 69.6 ± 10.9** 71.5
Bidi 108 86.6 15.2 ± 9.2* 12.2 15.5 ± 6.4** 14.5 69.3 ± 12.8** 71.8
Chewing tobacco 56 82.0 14.2 ± 7.0 13.3 15.8 ± 6.4** 14.7 70.0 ± 11.4** 71.9
Women
Nonea 352 69.0 12.9 ± 7.5 11.2 10.1 ± 4.9 9.3 77.0 ± 9.9 79.3
Cigarettes 1 — 9.1 — 10.9 — 80.0 —
Bidi 1 — 8.9 — 13.0 — 78.1 —
Chewing tobacco 157 89.4 12.4 ± 8.0 10.5 12.7 ± 5.5** 12.2 74.9 ± 11.3* 77.4
aReference group. *p < 0.05. **p < 0.01.
Table 3. ORs for arsenic-related skin lesions in relation to tobacco use among the 528 referents and 504 
skin lesion cases, stratified by sex.
Referents (n) Cases (n) ORcrude (95% CI) ORadj (95% CI)a ORmethylation (95% CI)b
Men
None 142 83 1.0 1.0 1.0
Cigarettes/bidi 83 157 3.2 (2.2–4.7)** 1.8 (1.1–3.1)* 1.4 (0.80–2.4)
Chewing tobacco 24 32 2.3 (1.3–4.1)** 0.80 (0.36–1.7) 0.60 (0.27–1.4)
Tobacco use 107 189 3.0 (2.1–4.3)** 1.6 (1.0–2.7) 1.2 (0.72–2.1)
Women
None 220 132 1.0 1.0 1.0
Tobacco usec 59 100 2.8 (1.9–4.2)** 2.4 (1.4–3.9)** 2.0 (1.2–3.4)**
aAdjusted for age, SES, and cumulative arsenic exposure; bAdjusted for age, SES, cumulative arsenic exposure, and 
%MA; cMainly tobacco chewing; only two women smoked. *p < 0.05. **p < 0.01. Lindberg et al.
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with nonusers of tobacco within the same ter-
tile (p = 0.009; Table 5). Women in the high-
est %MA tertile who chewed tobacco had an 
OR of 7.3 (95% CI, 3.4–15), compared with 
women in the lowest %MA group who did not 
use tobacco. This OR was higher than the pre-
dicted additive risks (5.7), although the RERI 
was not statistically significant (1.5; 95% CI, 
–3.7 to 6.7). Similarly, the ORjoint for women 
in the highest %iAs tertile who used tobacco 
was 7.5, which was higher than the predicted 
additive risks (2.5). The RERI was 5.0 (95% 
CI, –1.3 to 11.4), the attributable proportion 
due to interaction was 0.67 (0.36–0.98), and 
the synergy index was 4.4 (1.2–16), which 
indicated a biologic interaction. 
Discussion 
This population-based case–referent study in 
Bangladesh is the first to evaluate the combined 
effects of arsenic exposure, arsenic metabolism, 
and use of tobacco for the risk of arsenic-related 
skin effects. All forms of tobacco use were asso-
ciated with less efficient methylation of arsenic. 
Among men, there appeared to be an additive 
effect of poor arsenic methylation (high iAs 
and high %MA) and smoking for the develop-
ment of arsenic-induced skin lesions, although 
a high %MA increased the risk more than did 
smoking. Because very few women smoked 
cigarettes or bidis, an interaction between arse-
nic methylation and smoking in women could 
not be evaluated. Another new finding in the 
present study was that tobacco chewing, which 
is much more common among Bangladeshi 
women than smoking, was also a risk factor 
for developing arsenic-related skin lesions in 
women. The high ORs for skin lesions among 
the women who chewed tobacco in the high-
est tertiles of %iAs or %MA (7.5 and 7.3, 
respectively), compared with nontobacco using 
women with efficient arsenic methylation, sug-
gest an interaction, although the RERI values 
were not quite significant. For men, an associa-
tion between chewing tobacco and skin lesions 
was observed in the crude analysis only, but 
the sample size was small and the CIs wide. 
Further studies on larger cohorts are warranted 
for firm conclusions concerning the biologic 
interactions between various tobacco use, arse-
nic exposure, and arsenic metabolism. In any 
case, the use of various forms of tobacco should 
be considered in the risk assessment of arsenic 
and in the comparison of arsenic-related health 
risks among populations. 
Tobacco smoking has been identified as an 
independent risk factor of non  melanoma skin 
cancer (De Hertog et al. 2001; Grant 2008; 
Grodstein et al. 1995), psoriasis (Setty et al. 
2007), and premature skin aging (Just et al. 
2007; Morita 2007), but few studies have 
investigated the modifying effect of smoking 
on the arsenic-related hyper  pigmentation and 
hyperkeratosis. Chen et al. (2006) reported a 
significant synergistic effect between the high-
est level of arsenic exposure via drinking water 
(> 113 µg/L) and tobacco smoking for the 
risk of skin lesions among Bangladeshi men, 
but much weaker interaction effects among 
women. These authors suggested that the inter-
action could be due to immuno  suppression 
caused by tobacco smoking, inhibition of 
Table 4. Joint effect of arsenic metabolites in urine and tobacco use for the risk of arsenic-related skin 
lesions among men.
Groupsa Referents (n) Cases (n) ORstrat (95% CI)b,c ptrend ORjoint (95% CI)c
%iAs
None
≤ 9.5 49 22 1.0 1.0
9.5–13 42 25 1.3 (0.54–3.3) 1.2 (0.53–2.7)
> 13 51 36 2.2 (0.93–5.3) 0.07 1.6 (0.77–3.5)
Tobacco userd
≤ 9.5 24 46 1.0 1.9 (0.8–4.4)
9.5–13 39 48 0.64 (0.32–1.3) 1.3 (0.58–2.9)
> 13 44 95 1.1 (0.57–2.3) 0.5 2.8 (1.3–5.8)**
%MA
None
≤ 7.9 48 8 1.0 1.0
7.9–12 51 21 1.1 (0.36–3.1) 1.3 (0.48–3.5)
> 12 43 54 3.3 (1.3–9.2)* 0.003 3.8 (1.5–9.6)**
Tobacco userd
≤ 7.9 14 11 1.0 1.8 (0.53–6.3)
7.9–12 24 27 1.2 (0.42–3.3) 2.4 (0.80–6.9)
> 12 69 151 2.1 (0.86–5.2) 0.03 4.4 (1.7–11)**
%DMA
None
≤ 76 53 50 1.0 1.0
76–82 44 24 0.62 (0.28–1.4) 0.60 (0.29–1.2)
> 82 45 9 0.25 (0.090–0.71)** 0.008 0.31 (0.13–0.77)*
Tobacco userd
≤ 76 65 140 1.0 1.4 (0.77–2.6)
76–82 29 32 0.47 (0.25–0.90)* 0.58 (0.27–1.3)
> 82 13 17 0.72 (0.30–1.7) 0.1 0.78 (0.29–2.1)
aTertiles of referents. bOR for the groups stratified by level of arsenic metabolites. cAdjusted for age, SES, and cumulative 
arsenic exposure. dOf the participants who used tobacco, 78% of the referents and 83% of the cases smoked cigarettes 
or bidis. See also Supplemental Material, Tables S1 and S2 (doi:10.1289/ehp.0900728). *p < 0.05. **p < 0.01. 
Table 5. Joint effect of arsenic metabolites in urine and tobacco use for the risk of arsenic-related skin 
lesions among women.
Groupsa Referents (n) Cases (n) ORstrat (95% CI)b,c ptrend ORjoint (95% CI)c
%iAs
None
≤ 9.5 74 40 1.0 1.0
9.5–13 82 32 0.96 (0.50–1.8) 0.89 (0.48–1.7)
> 13 64 60 1.9 (1.0–3.4)* 0.04 1.7 (0.95–3.1)
Tobacco used
≤ 9.5 28 33 1.0 1.8 (0.83–3.8)
9.5–13 23 27 0.85 (0.36–2.0) 1.9 (0.89–4.2)
> 13 8 40 2.5 (0.88–6.9) 0.1 7.5 (3.0–19)**
%MA
None
≤ 7.9 102 34 1.0 1.0
7.9–12 76 40 1.4 (0.74–2.5) 1.4 (0.76–2.5)
> 12 42 58 2.8 (1.5–5.2)** 0.002 2.9 (1.6–5.5)**
Tobacco used
≤ 7.9 13 16 1.0 3.8 (1.4–10)**
7.9–12 27 22 0.38 (0.12–1.2) 1.6 (0.73–3.6)
> 12 19 62 1.6 (0.55–4.8) 0.06 7.3 (3.4–15)**
%DMA
None
≤ 76 57 66 1.0 1.0
76–82 82 36 0.35 (0.19–0.64)** 0.37 (0.20–0.66)**
> 82 81 30 0.39 (0.21–0.72)** 0.002 0.39 (0.21–0.72)**
Tobacco used
≤ 76 12 51 1.0 3.2 (1.4–7.1)**
76–82 27 26 0.26 (0.10–0.66)** 0.66 (0.31–1.4)
> 82 20 23 0.40 (0.15–1.1) 0.06 0.98 (0.43–2.2)
aTertiles of referents. bOR for the groups stratified by level of arsenic metabolites. cAdjusted for age, SES, and cumula-
tive arsenic exposure. dMainly tobacco chewing; only two women smoked. *p < 0.05. **p < 0.01.Tobacco use and arsenic-induced skin lesions
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arsenic methylation, or the prevalent smoking 
of bidis, the filterless, locally produced ciga-
rettes with raw tobacco. Bidis are popular in 
rural areas in Bangladesh and are claimed to 
contain more carcinogenic substances than do 
cigarettes. 
In the present study, the effect of smok-
ing on arsenic-related skin lesions was studied 
only in men, because, by tradition, very few 
women in Bangladesh are smokers. According 
to personal interviews, almost half the men 
were smokers, whereas only two of more than 
500 women smoked. It is highly unlikely 
that we have any differential misclassifica-
tion in the data on tobacco use. Smoking or 
other forms of tobacco use are not linked to 
any stigma and are in no way considered to 
be associated with the arsenic-induced skin 
lesions by the study population. The increased 
risk of skin lesions among men who smoked 
was not due to additional exposure to arsenic 
via smoking. The concentrations of arsenic in 
different brands of cigarettes from local shops 
in Matlab ranged between 0.13 and 0.29 µg/g 
(mean 0.21 µg/g, n = 5) and between 0.24 
and 0.27 µg/g (mean 0.25 µg/g, n = 3) for 
bidis. Thus, it could be estimated that the 
inhaled amount of arsenic by smoking 10 
cigarettes or bidis/day, for example, was about 
2 µg. Even though a considerable part of this 
arsenic is absorbed in the lungs, the arsenic 
uptake from smoking is negligible compared 
with that from drinking water (70% of the 
wells had > 10 µg As/L; Rahman et al. 2006b) 
and food (Lindberg et al. 2008a).
Instead, we found that smoking was asso-
ciated with higher %MA in urine, which 
is a known risk factor for arsenic-related 
skin effects (Ahsan et al. 2007; Chen et al. 
2003a; Del Razo et al. 1997; Hsueh et al. 
1997; Lindberg et al. 2008a; Yu et al. 2000). 
Elevated %MA in urine may be related to the 
highly toxic trivalent intermediate metabo-
lite MA(III) (Ganyc et al. 2007; Vega et al. 
2001) in the tissues, including skin (Vahter 
2002). The decrease in the second step in the 
methylation of arsenic (to DMA) by smok-
ing is in agreement with previous findings 
(Hopenhayn-Rich et al. 1996; Lindberg et al. 
2008b); however, the mechanism by which 
this occurs is not clear. It may be that smoking 
inhibits the specific AS3MT involved in arsenic 
methylation or impairs one-carbon metabo-
lism in general. Cigarette smoking is known 
to increase serum homocysteine concentra-
tion (O’Callaghan et al. 2002; Refsum et al. 
2006), which, via the concurrent accumula-
tion of S-adenosylhomocysteine, exerts a strong 
inhibition of S-adenosylmethionine–dependent 
transmethylation reactions, including those 
of arsenic (Gamble et al. 2005; Marafante 
and Vahter 1984). Smokers also tend to have 
lower levels of folate and vitamin B6 and B12 
(O’Callaghan et al. 2002), all of which are 
essential for homocysteine metabolism. The 
smoking-related increase in homocysteine is 
most likely less pronounced in women, in 
whom the estrogen-dependent upregulation of 
endogenous choline synthesis may, via oxida-
tion to betaine, contribute to remethylation of 
homocysteine (Zeisel 2007). Indeed, the study 
by Chen et al. (2006) observed a much stron-
ger effect of smoking on arsenic-related skin 
lesions in men than in women. 
Another new finding in this study is that 
chewing tobacco is a risk factor for arsenic-
related skin effects for women and that there 
appears to be an interaction with poor metabo-
lism of arsenic. For men, the effect of chew-
ing tobacco on the risk of skin lesion seems to 
be much less, but the number of cases is too 
small for a firm conclusion. About 31% of 
the women reported chewing tobacco, which 
locally is called shada (dried tobacco leaves) 
or zarda (processed tobacco leaves in a paste) 
(Choudhury et al. 2007). In zarda, the tobacco 
is often mixed with sliced areca nut, lime, and 
sometimes a leaf of the piper betel plant, and 
the adverse effects may be caused by this mix-
ture rather than the tobacco alone. Areca nut, 
the seed of Areca catechu, is used in a variety 
of chewed products, often mixed with tobacco 
or betel leaves. Both betel quid and areca nut 
have been associated with increased risk for 
oral epithelial malignancy (IARC 2004b; Lee 
et al. 2008). In a previous study in Bangladesh, 
McCarty et al. (2006) reported that betel nut 
use, but not tobacco chewing or cigarette 
smoking, was associated with skin lesions. As 
that study matched by sex, it is not known if 
the associations were sex dependent. In the 
present study, zarda contained about half a 
microgram of arsenic per gram of tobacco 
(0.33–0.54 µg/g; mean 0.45 µg/g; n = 8), 
which is about twice as much as in cigarettes 
and bidis. Still, the arsenic exposure from chew-
ing zarda was low compared with that from the 
drinking water and food.
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